BMY 14802

BMY 14802 is a sigma-1 receptor (σ1R) antagonist, as well as an agonist at serotonin (5-HT) 1A and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM[1][2].

Product Specifications

CAS Number

[105565-56-8]

UNSPSC

12352005

Target

5-HT Receptor; Adrenergic Receptor; Sigma Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/bmy-14802.html

Concentration

10mM

Purity

98.96

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC1=CN=C(N2CCN(CCCC(C3=CC=C(C=C3)F)O)CC2)N=C1

Molecular Formula

C18H22F2N4O

Molecular Weight

348.39

References & Citations

[1]Paquette MA, et al. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology (Berl) . 2009 Jul;204 (4) :743-54. |[2]Paquette MA, et al. Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. Neuroreport. 2008 Jan 8;19 (1) :111-5.